Low-dose deoxycoformycin in lymphoid malignancy.
- 1 September 1985
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 3 (9), 1196-1201
- https://doi.org/10.1200/jco.1985.3.9.1196
Abstract
Deoxycoformycin (dCF), a potent inhibitor of adenosine deaminase (ADA), was explored for its antineoplastic potential in 28 patients with advanced lymphoid malignancy. Both normal and malignant B lymphocytes have low levels of ADA activity, and low doses of dCF profoundly inhibit this enzyme in the peripheral blood of patients with chronic lymphocytic leukemia (CLL). The low doses of dCF administered in this trial (4 mg/m2) were not associated with prohibitive toxicity. Five of 28 patients had an objective response. Four additional patients had clinical improvement. No significant difference in the pretreatment ADA activity existed between responding patients and treatment failures. The demonstration of responses to dCF following failure on standard alkylating agents suggests that dCF may not be cross-resistant with current agents used to treat CLL. Additional studies should be pursued using low-dose dCF in patients with advanced malignancy.This publication has 20 references indexed in Scilit:
- THE BIOCHEMICAL AND CLINICAL CONSEQUENCES OF 2'-DEOXYCOFORMYCIN IN REFRACTORY LYMPHOPROLIFERATIVE MALIGNANCY1981
- REMISSION INDUCTION WITH ADENOSINE-DEAMINASE INHIBITOR 2'-DEOXYCOFORMYCIN IN THY-LYMPHOBLASTIC LEUKÆMIAThe Lancet, 1980
- Purinogenic Immunodeficiency Diseases: Clinical Features and Molecular MechanismsAnnals of Internal Medicine, 1980
- TREATMENT OF ACUTE LYMPHOBLASTIC-LEUKEMIA WITH 2'-DEOXYCOFORMYCIN - CLINICAL AND BIOCHEMICAL CONSEQUENCES OF ADENOSINE-DEAMINASE INHIBITION1979
- Differential Sensitivity of Human Leukemic T Cell Lines and B Cell Lines to Growth Inhibition by DeoxyadenosineThe Journal of Immunology, 1978
- Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency.Journal of Biological Chemistry, 1978
- Guidelines for protocol studies in chronic lymphocytic leukemiaAmerican Journal of Hematology, 1978
- Two Biochemical Markers in Lymphocyte SubpopulationsBritish Journal of Haematology, 1976
- Adenosine deaminase activity in chronic lymphocytic leukemia. Relationship to B- and T-cell subpopulations.JCI Insight, 1976
- THE CLINICAL IMPLICATIONS OF HYPOGAMMAGLOBULINEMIA IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND LYMPHOCYTIC LYMPHOSARCOMAAnnals of Internal Medicine, 1959